|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
gptkb:physician
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
N06DX01
|
|
gptkbp:brand
|
gptkb:Aduhelm
|
|
gptkbp:CASNumber
|
1384266-65-4
|
|
gptkbp:chemicalClass
|
gptkb:monoclonal_antibody
|
|
gptkbp:clinicalTrialPhase
|
Phase 3
NCT02477800
NCT02484547
|
|
gptkbp:compatibleWith
|
gptkb:Canada
gptkb:Japan
gptkb:European_Medicines_Agency
|
|
gptkbp:controversy
|
high cost
FDA approval process
efficacy debated
|
|
gptkbp:developedBy
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:halfLife
|
24.8 days
|
|
gptkbp:hasMolecularFormula
|
C6470H9954N1714O2018S46
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Aducanumab
|
|
gptkbp:immunoglobulinType
|
gptkb:IgG1
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:macromoleculeType
|
gptkb:amyloid_beta
|
|
gptkbp:marketWithdrawal
|
2024
|
|
gptkbp:marketWithdrawalReason
|
lack of demand
|
|
gptkbp:mechanismOfAction
|
reduces amyloid beta plaques
|
|
gptkbp:monoclonalAntibodyType
|
gptkb:human
|
|
gptkbp:origin
|
gptkb:Switzerland
|
|
gptkbp:patent
|
gptkb:Biogen
gptkb:Neurimmune
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:prescriptionRequired
|
available from FDA
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
gptkb:amyloid-related_imaging_abnormalities_(ARIA)
confusion
nausea
dizziness
headache
|
|
gptkbp:storage
|
2–8°C
|
|
gptkbp:targetDiseaseStage
|
mild cognitive impairment
mild Alzheimer's disease
|
|
gptkbp:trialSponsor
|
gptkb:Biogen
gptkb:Eisai
|
|
gptkbp:UNII
|
8Z6Q2R73AG
|
|
gptkbp:usedFor
|
gptkb:Alzheimer's_disease
|
|
gptkbp:bfsParent
|
gptkb:Biogen_Inc.
|
|
gptkbp:bfsLayer
|
7
|